Biorelevant media simulating fed state intestinal fluids: Colloid phase characterization and impact on solubilization capacity

Journal of Pharmaceutical Sciences

Volumn 99, Issue 8, 2010, Pages 3522-3532

  Kleberg, Karen ^a   Jacobsen, Freja ^a   Fatouros, Dimitris G ^b   Müllertz, Anette ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Biorelevant media; Cryo TEM; Poorly soluble drug compounds; Solubilization

Indexed keywords

CINNARIZINE; DANAZOL; FATTY ACID; FENOFIBRATE; GLYCEROL OLEATE; MONOACYLGLYCEROL; NANOMATERIAL; OLEIC ACID; SURFACTANT; COLLOID; EMULSION; MICELLE; SOLUTION AND SOLUBILITY;

ARTICLE; CULTURE MEDIUM; ELECTRON TOMOGRAPHY; INTESTINE FLUID; LIGHT SCATTERING; LIPOLYSIS; MICELLE; PARTICLE SIZE; SIMULATION; SOLUBILIZATION; SURFACE TENSION; ALGORITHM; BILE; BODY FLUID; CHEMISTRY; COLLOID; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE; LIGHT; METABOLISM; RADIATION SCATTERING; SOLUBILITY; SOLUTION AND SOLUBILITY; TRANSMISSION ELECTRON MICROSCOPY;

ALGORITHMS; BILE; BODY FLUIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CINNARIZINE; COLLOIDS; DANAZOL; EMULSIONS; FATTY ACIDS, NONESTERIFIED; FENOFIBRATE; INTESTINES; LIGHT; MICELLES; MICROSCOPY, ELECTRON, TRANSMISSION; MONOGLYCERIDES; PARTICLE SIZE; SCATTERING, RADIATION; SOLUBILITY; SOLUTIONS; SURFACE TENSION;

EID: 77955097506     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22122     Document Type: Article

References (24)

1. Lennernas H. 2007. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: Experience from in vivo dissolution and permeability studies in humans. Curr Drug Metab 8:645-657.
2. Pouton CW. 2006. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29:278-287.
3. Bates TR, Gibaldi M, Kanig JL. 1966. Solubilizing properties of bile salt solutions. II. Effect of inorganic electrolyte, lipids, and a mixed bile salt system on solubilization of glutethimide, griseofulvin, and hexestrol. J Pharm Sci 55:901-906.
4. Luner PE, Vander KD. 2001. Wetting behavior of bile salt-lipid dispersions and dissolution media patterned after intestinal fluids. J Pharm Sci 90:348-359.
5. Charman WN, Rogge MC, Boddy AW, Berger BM. 1993. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J Clin Pharmacol 33:381-386.
6. Crounse RG. 1963. Effective use of griseofulvin. Arch Dermatol 87:176-178.
7. Sunesen VH, Pedersen BL, Kristensen HG, Mullertz A. 2005. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur J Pharm Sci 24:305-313.
8. Kalantzi L, Persson E, Polentarutti B, Abrahamsson B, Goumas K, Dressman JB, Reppas C. 2006. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res 23:1373-1381. (Pubitemid 43946159)
9. Persson EM, Gustafsson AS, Carlsson AS, Nilsson RG, Knutson L, Forsell P, Hanisch G, Lennernas H, Abrahamsson B. 2005. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 22: 2141-2151.
10. Fatouros DG, Walrand I, Bergenstahl B, Mullertz A. 2009. Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products. Pharm Res 26: 361-374.
11. Dubochet J, Adrian M, Chang JJ, Homo JC, Lepault J, McDowall AW, Schultz P. 1988. Cryo-electron microscopy of vitrified specimens. Q Rev Biophys 21:129-228.
12. Bellare JR, Davis HT, Scriven LE, Talmon Y. 1988. Controlled environment vitrification system: An improved sample preparation technique. J Electron Microsc Tech 10:87-111.
13. Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C. 2006. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/ bioequivalence studies. Pharm Res 23:165-176.
14. Cardenas M, Schillen K, Alfredsson V, Duan RD, Nyberg L, Arnebrant T. 2008. Solubilization of sphingomyelin vesicles by addition of a bile salt. Chem Phys Lipids 151:10-17. (Pubitemid 350161885)
15. Cistola DP, Hamilton JA, Jackson D, Small DM. 1988. Ionization and phase behavior of fatty acids in water: Application of the Gibbs phase rule. Biochemistry 27:1881-1888.
16. Mansbach CM, Cohen RS, Leff PB. 1975. Isolation and properties of the mixed lipid micelles present in intestinal content during fat digestion in man. J Clin Invest 56:781-791.
17. Hjelm RP, Thiyagarajan P, kan-Onyuksel H. 1992. Organization of phosphatidylcholine and bile salt in rodlike mixed micelles. J Phys Chem 96:8653-8661.
18. Rigler MW, Patton JS. 1983. The production of liquid crystalline product phases by pancreatic lipase in the absence of bile salts. A freeze-fracture study. Biochim Biophys Acta 751:444-454.
19. Borne J, Nylander T, Khan A. 2003. Vesicle formation and other structures in aqueous dispersions of monoolein and sodium oleate. J Colloid Interface Sci 257:310-320.
20. Cistola DP, Atkinson D, Hamilton JA, Small DM. 1986. Phase behavior and bilayer properties of fatty acids: Hydrated 1:1 acid-soaps. Biochemistry 25:2804-2812. (Pubitemid 16073814)
21. Staggers JE, Hernell O, Stafford RJ, Carey MC. 1990. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry 29: 2028-2040.
22. Carey MC, Small DM. 1970. The characteristics of mixed micellar solutions with particular reference to bile. Am J Med 49:590-608.
23. Zangenberg NH, Mullertz A, Kristensen HG, Hovgaard L. 2001. A dynamic in vitro lipolysis model. II: Evaluation of the model. Eur J Pharm Sci 14:237-244.
24. Kaukonen AM, Boyd BJ, Porter CJ, Charman WN. 2004. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. Pharm Res 21: 245-253.